New hope for prostate cancer: enzalutamide slows progression in asian men
NCT ID NCT02294461
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 study tested the drug enzalutamide in 395 Asian men with metastatic prostate cancer that had stopped responding to standard hormone therapy. Participants had not yet received chemotherapy. The study compared enzalutamide to a placebo to see if it could delay rises in PSA levels, a marker of cancer progression. The goal was to assess whether enzalutamide could help control the disease for a longer time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
enzalutamide (Xtandi)
What this could lead to
If successful, enzalutamide could offer a new treatment option to delay cancer progression in men with metastatic prostate cancer who have not yet had chemotherapy.
What could go wrong
This trial is completed, but results may not apply to all populations. Enzalutamide can cause side effects like fatigue, high blood pressure, and falls. It controls the disease, not cures it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CN00102
Shanghai, China
-
CN00103
Beijing, China
-
CN00104
Beijing, China
-
CN00105
Shanghai, China
-
CN00106
Beijing, China
-
CN00107
Hangzhou, China
-
CN00108
Shanghai, China
-
CN00109
Wuhan, China
-
CN00110
Nanjing, China
-
CN00111
Beijing, China
-
CN00112
Beijing, China
-
CN00113
Shanghai, China
-
CN00114
Beijing, China
-
CN00115
Beijing, China
-
CN00117
Nanjing, China
-
CN00118
Wenzhou, China
-
CN00119
Suzhou, China
-
CN00121
Changsha, China
-
CN00124
Xi'an, China
-
CN00125
Tianjin, China
-
CN00126
Shanghai, China
-
CN00127
Beijing, China
-
HK00402
Hong Kong, Hong Kong
-
KR00201
Incheon, South Korea
-
KR00202
Seongnam-si, South Korea
-
KR00203
Daegu, South Korea
-
KR00204
Seoul, South Korea
-
KR00205
Busan, South Korea
-
KR00206
Seoul, South Korea
-
KR00207
Busan, South Korea
-
KR00208
Seoul, South Korea
-
KR00209
Seoul, South Korea
-
KR00210
Seoul, South Korea
-
KR00211
Seoul, South Korea
-
KR00212
Cheongju-si, South Korea
-
KR00213
Daejeon, South Korea
-
KR00214
Anyang, South Korea
-
KR00215
Seoul, South Korea
-
TW00301
Taipei, Taiwan
-
TW00302
Taichung, Taiwan
-
TW00303
Taichung, Taiwan
-
TW00304
Taipei, Taiwan
-
TW00305
Taoyuan County, Taiwan
-
TW00306
Taipei, Taiwan
-
TW00307
Tainan, Taiwan
-
TW00308
Tainan, Taiwan
-
TW00309
Kaohsiung City, Taiwan